All In Biotech

Drug Trial Radar · NCT07194850

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 20, 2025

Primary completion

Oct 2028

Study completion Oct 2030

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Sep 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP). The study consists of a double-blinded treatment period (DBTP) in which the participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV. At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first year open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second year (OLTP2). After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancejunior

Conditions

  • Immune Thrombocytopenia (ITP)
  • ITP - Immune Thrombocytopenia
  • ITP
  • Immune Thrombocytopenic Purpura
  • Immune Thrombocytopenic Purpura ( ITP )
  • Idiopathic Thrombocytopenic Purpura
  • Idiopathic Thrombocytopenic Purpura (ITP)

Interventions

  • Efgartigimod IVBiological

    Intravenous infusion of efgartigimod

  • Placebo IVOther

    Intravenous infusion of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efgartigimod serum concentrations in the DBTPTime frame: Up to 24 weeks
  2. Total IgG levels in the DBTPTime frame: Up to 24 weeks

Locations

28 sites in 10 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin Hopital des Enfants

    Bordeaux, France · Recruiting

  • Centre Hospitalier Universitaire de Grenoble - Hopital Couple - Enfant

    La Tronche, France · Recruiting

  • CHU de Nancy Hopitaux de Brabois

    Vandœuvre-lès-Nancy, France · Recruiting

  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Freiburg Kinder - Kinder- und Jugendklinik

    Freiburg im Breisgau, Germany · Recruiting

  • Gaslini Children's Hospital

    Genoa, Italy · Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Italy · Recruiting

  • Bambino Gesu Children's Hospital

    Roma, Italy · Recruiting

  • A.O.U. Citta della Salute e della Scienza di Torino - Ospedale Infantile Regina Margherita

    Torino, Italy · Recruiting

  • Saitama Prefectural Children's Medical Center

    Saitama, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Hyogo Prefectural Kobe Children's Hospital

    Kobe, Hyōgo, Japan · Recruiting

  • Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital

    Osaka, Osaka, Japan · Recruiting

  • Vilnius University Hospital Santaros Klinikos, Children's Hospital

    Vilnius, Lithuania · Recruiting

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny nr 4

    Lodz, Poland · Recruiting

  • Uniwersytecki Szpital Dzieciecy w Lublinie

    Lublin, Poland · Recruiting

  • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego

    Warsaw, Poland · Recruiting

  • Institutul Clinic Fundeni

    Bucharest, Romania · Recruiting

  • Institute Of Mother And Child Healthcare Of Serbia Dr Vukan Cupic

    Belgrade, Serbia · Recruiting

  • University Clinical Centre of Kragujevac

    Kragujevac, Serbia · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Sant Joan de Deu Barcelona

    Esplugues de Llobregat, Spain · Recruiting

  • Hospital Infantil Universitario Nino Jesus (HIUNJS)

    Madrid, Spain · Recruiting

  • Hospital Materno-Infantil Universitario Gregorio Maranon

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Cardiff and Vale NHS Trust - University Hospital of Wales (UHW)

    Cardiff, United Kingdom · Recruiting

  • The Royal Hospital for Children - Glasgow Health Board

    Glasgow, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital - Manchester University NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.